In a nutshell
This study investigated the effects of serenoa repens extract in the treatment of benign prostatic hyperplasia (BPH). Researchers concluded that serenoa repens reduces prostate inflammatory markers in a selected group of patients.
Some background
Benign prostatic hyperplasia (BPH) may lead to bothersome urinary symptoms, and is often accompanied by chronic inflammation of the prostate gland. Previous studies have demonstrated that serenoa repens extract (Permixon) has potent anti-inflammatory properties. This study investigated the effects of serenoa repens extract in the treatment of BPH related urinary symptoms.
Methods & findings
206 men with BPH related urinary symptoms were included in this study. Men were randomized to receive serenoa repens extract, or tamsulosin (a potent anti-inflammatory drug, used as the control for this trial). Men were followed during 3 months of treatment. Urine tests were checked at the beginning and end of treatment to assess BPH related inflammation markers (molecules which indicate an inflammatory process is present). Men were also asked to report changes in symptoms and urinary function using a standard questioner.
65.4% of the markers detected in the serenoa repens group were decreased after treatment, compared to 46.2% of the markers in the tamsulosin control group. Among the 15 most common markers, this difference was even higher (80% compared to 33%). Three markers in particular were found to respond significantly well to serenoa repens treatment (MCP-1/CCL2, IP-10/CXCL10, and MIF). Among men with high levels of the MIF marker and treated with serenoa repens, a greater improvement in patient reported symptoms was noted.
The bottom line
This study concluded that serenoa repens extract may reduce prostate inflammation and contribute to the care of men with benign prostatic hyperplasia.
The fine print
The results of this exploratory study should be confirmed in additional clinical trials.
Published By :
Prostate
Date :
Dec 01, 2015
